<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01196650</url>
  </required_header>
  <id_info>
    <org_study_id>IN 10 003</org_study_id>
    <nct_id>NCT01196650</nct_id>
  </id_info>
  <brief_title>Comparison of IN 10 003 to Placebo in Subjects With Insomnia Suffering From Difficulty in Falling Asleep and Staying Asleep</brief_title>
  <official_title>A Double Blind, Polysomnographic, Three-Way Crossover Study to Compare the Efficacy of IN 10 003 to Placebo in Subjects With Insomnia Suffering From Difficulty in Falling Asleep and Staying Asleep</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intec Pharma Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intec Pharma Ltd.</source>
  <brief_summary>
    <textblock>
      This study aims to assess the efficacy of IN 10 003 in improving sleep parameters in patients
      with Insomnia exhibiting both difficulty in falling asleep and staying asleep. The study will
      compare 2 formulations of the IN 10 003 to placebo
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wake after sleep onset</measure>
    <description>To determine the effect of IN 10 003 on Wake time After Sleep Onset (WASO) as the change from baseline for the mean of night 1 and 2 relative to placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective and Subjective sleep parameters</measure>
    <description>Total Sleep Time, Latency to Persistent Sleep, Absence of residual effects,</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Subjects With Insomnia Suffering From Difficulty in Falling Asleep and Staying Asleep</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IN 10 003 formulation A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IN 10 003 formulation B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IN 10 003 formulation A</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IN 10 003 formulation B</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsules</intervention_name>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects between the ages of 18 and 65 years of age

          -  Subjects that meet DSM IV diagnostic criteria for Insomnia

          -  Subjects that report a time in bed NLT 6.5 and NMT 9 hours

          -  Subjects that report on a one week sleep diary (on at least 3 of 7 nights) TST NMT 6.5
             hours

          -  Subjects that report on a one week sleep diary (on at least 3 of 7 nights) Wake time
             after sleep &gt;1.0 hour

          -  Subjects that report on a one week sleep diary (on at least 3 of 7 nights) NLT 30
             minutes time to sleep onset

          -  On two nights of PSG screening a mean WASO of ≥60 minutes with neither night less than
             45 minutes

          -  On two nights of PSG screening a mean LPS of ≥20 minutes with neither night less than
             15 minutes

          -  On two nights of PSG screening a TST of NMT 6.5 hours on each of the two nights

        Exclusion Criteria:

          -  Subject has a circadian rhythm disorder including shift work or the need to travel NLT
             3 time zones during the course of the study

          -  Use of any drug known to effect sleep or wake functions within 5 half lives of the
             drug or two weeks, whichever comes first.

          -  Subject with a history (past year) of alcohol or substance abuse

          -  Subject that needs to smoke during the sleep period time

          -  Subject that reports habitual napping (more than 3 times per week)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assuta Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2010</study_first_submitted>
  <study_first_submitted_qc>September 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2010</study_first_posted>
  <last_update_submitted>May 2, 2011</last_update_submitted>
  <last_update_submitted_qc>May 2, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2011</last_update_posted>
  <responsible_party>
    <name_title>Hadas Friedman</name_title>
    <organization>Intec Pharma Ltd.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
    <mesh_term>Stress, Psychological</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

